Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Condition:   Cystic Fibrosis Interventions:   Dietary Supplement: Resveratrol;   Dietary Supplement: NR;   Dietary Supplement: Placebo Sponsor:   Virginia Commonwealth University Not yet recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Behavioral: Guided Grocery Shopping (GGS);   Other: Diet Provision Group Sponsors:   Emory University;   Center for Cystic Fibrosis and Airways Disease Research Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Interventions:   Other: Autogenic drainage;   Device: SIMEOX + Autogenic drainage Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain Recruiting
Source: - Category: Research Source Type: clinical trials
AbstractThe contribution of T-cells after lung transplant (LTx) remains controversial with no current consensus of their role concerning chronic lung allograft dysfunction. Using flow cytometry to assess T-cell subsets of bronchoalveolar lavage fluid (BALF) in 16 cystic fibrosis (CF) LTx recipients, we identified a decline in CD4+ T-cell frequency and an increase in CD8+ T-cell frequency in patients who developed severe bronchiolitis obliterans syndrome (BOS) (N = 10) when comparing baseline (6 months post-LTx) and follow-up (most recent bronchoscopy—clinical or surveillance per protocol). Comparin...
Source: Lung - Category: Respiratory Medicine Source Type: research
ConclusionsThe synbiotic had no significant effect on pulmonary and anthropometric outcomes in children with CF. Further studies are necessary to confirm these findings.
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
For the past four years, a research session at the annual European Cystic Fibrosis Society (ECFS) meeting has been co-hosted by The Lancet Respiratory Medicine and the Journal of Cystic Fibrosis. At the 2020 ECFS meeting in June in Lyon, France, we are pleased to announce that the European Respiratory Journal will join this session for the first time.
Source: European Respiratory Journal - Category: Respiratory Medicine Tags: Call for papers Source Type: research
Condition:   Cystic Fibrosis Interventions:   Drug: ELX/TEZ/IVA;   Drug: IVA Sponsor:   Vertex Pharmaceuticals Incorporated Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Journal of Medicinal ChemistryDOI: 10.1021/acs.jmedchem.9b01416
Source: Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research
All-cause mortality risk and causes of death in bronchiectasis patients have not been fully investigated. The aim of this study was to compare the mortality risk and causes of death between individuals with br...
Source: Respiratory Research - Category: Respiratory Medicine Authors: Tags: Research Source Type: research
‘First step’ to better outcomes for cystic fibrosis Related items fromOnMedica Lung experts call for ‘national plan for lung cancer’ Smokers ’ lungs should remain as transplant option COPD patients need better tailored care Antibiotic fails to improve lung function in children with CF Sweet and fruity e-cigs linked to prolonged teenage vaping
Source: OnMedica Latest News - Category: UK Health Source Type: news
We present an alternative method for the identification of CF by combining desorption electrospray ionization mass...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Physical Sciences Source Type: research
More News: Cystic Fibrosis | Nutrition | Research | Sports Medicine